Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
motavizumab
- Development stage
- Discontinued
- Lead developer
- MedImmune
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Motavizumab is a second-generation, ultra-potent humanized monoclonal antibody derived from palivizumab using affinity maturation techniques. It targets the fusion (F) glycoprotein of respiratory syncytial virus (RSV), binding to a highly conserved antigenic site A on the F protein with much higher affinity than its predecessor. By binding to this protein, motavizumab inhibits RSV's ability to fuse with and enter host cells, thereby reducing viral replication and preventing infection. Motavizumab was developed for the prevention of serious RSV disease in high-risk pediatric patients but was discontinued for this indication after regulatory setbacks; development continues for other potential RSV treatments[1][3][4][5][7].
- Brand names
- Numax
- Other names
- IMMUNOGLOBULIN G1, ANTI-(RESPIRATORY SYNCYTIAL VIRUS GLYCOPROTEIN F) (HUMAN-MOUSE MONOCLONAL MEDI-524 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL MEDI-524.KAPPA.-CHAIN, DIMER
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on motavizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on motavizumab.